Charles River Laboratories International Inc
Change company Symbol lookup
Select an option...
CRL Charles River Laboratories International Inc
KIO KKR Income Opportunities Fund
BOAS BOA Acquisition Corp
ESBA Empire State Realty OP LP
CMS CMS Energy Corp
POWRU Powered Brands
VLDRW Velodyne Lidar Equity Warrants Exp 29 Sep 2025 *W EXP 09/29/2025
JPM JPMorgan Chase & Co
UVV Universal Corp

Health Care : Life Sciences Tools & Services | Mid Cap Growth
Company profile

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company provides products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions in research and drug development. The Company operates through two segments: Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing). The DSA segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions, and Avian Vaccine Services.


Last Trade
0.08 (0.03%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
Yesterday's News, January 27, 2022
Charles River Expands Strategic Partnership With SAMDI Tech

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of their strategic partnership with Chicago, Illinois-based SAMDI Tech, Inc. Under the existing partnership, established in 2018, SAMDI Tech clients have access...(BusinessWire)

January 20, 2022
Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2021 financial results on Wednesday, February 16th, before the market opens. A conference call has been scheduled to discuss this information on...(BusinessWire)

January 19, 2022
Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Access to AI-Enabled Drug Discovery Solutions

Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, LLC ("Valo"), the technology company using human-centric data and computation powered by artificial intelligence (AI) to transform the drug discovery and development...(BusinessWire)

January 11, 2022
Charles River Laboratories Announces Chief Financial Officer Retirement and Transition Plan

--Charles River Issues 2022 Financial Guidance in Conjunction with J.P. Morgan Healthcare Conference Charles River Laboratories International, Inc. (NYSE: CRL) today announced a retirement and transition plan for its Chief Financial Officer. (BusinessWire)

January 06, 2022
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11th, at 10:30 a.m. ET. Management will present an overview of Charles...(BusinessWire)

November 16, 2021
Charles River Laboratories to Participate in Upcoming Investor Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at two upcoming investor conferences, including: Jefferies London Healthcare Conference on Thursday, November 18th, with a pre-recording of the...(BusinessWire)

November 11, 2021
Charles River Laboratories Promotes Birgit Girshick to Chief Operating Officer

Charles River Laboratories International, Inc. (NYSE:CRL) today announced that Birgit Girshick has been promoted to the position of Chief Operating Officer, effective immediately. In her most recent role as Corporate Executive Vice President, Ms...(BusinessWire)

November 03, 2021
Charles River Laboratories Announces Third-Quarter 2021 Results

--- Third-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.70 - --- Updates 2021 Guidance - Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2021. For the...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.